266 related articles for article (PubMed ID: 12496469)
1. Tumor microenvironment and the response to anticancer therapy.
Brown JM
Cancer Biol Ther; 2002; 1(5):453-8. PubMed ID: 12496469
[TBL] [Abstract][Full Text] [Related]
2. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
Brown JM
Mol Med Today; 2000 Apr; 6(4):157-62. PubMed ID: 10740254
[TBL] [Abstract][Full Text] [Related]
3. Tumor hypoxia in cancer therapy.
Brown JM
Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia: targeting the tumour.
Boyle RG; Travers S
Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
[TBL] [Abstract][Full Text] [Related]
5. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Vordermark D; Brown JM
Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668
[TBL] [Abstract][Full Text] [Related]
6. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
7. Bioreductive drugs in cancer therapy.
Stratford IJ
BJR Suppl; 1992; 24():128-36. PubMed ID: 1341908
[No Abstract] [Full Text] [Related]
8. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
[TBL] [Abstract][Full Text] [Related]
10. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
Brown JM
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):12-4. PubMed ID: 9647614
[TBL] [Abstract][Full Text] [Related]
11. Tirapazamine: from bench to clinical trials.
Marcu L; Olver I
Curr Clin Pharmacol; 2006 Jan; 1(1):71-9. PubMed ID: 18666379
[TBL] [Abstract][Full Text] [Related]
12. Prospects for hypoxia-activated anticancer drugs.
Denny WA
Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):395-9. PubMed ID: 15379691
[TBL] [Abstract][Full Text] [Related]
13. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.
Denny WA; Wilson WR
Expert Opin Investig Drugs; 2000 Dec; 9(12):2889-901. PubMed ID: 11093359
[TBL] [Abstract][Full Text] [Related]
14. Tirapazamine: a novel agent targeting hypoxic tumor cells.
Reddy SB; Williamson SK
Expert Opin Investig Drugs; 2009 Jan; 18(1):77-87. PubMed ID: 19053884
[TBL] [Abstract][Full Text] [Related]
15. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells.
Xu P; Huang JM; Ren Y; Zha X; Deng BF; Wu JH; Lang JY
Chin J Cancer; 2010 Feb; 29(2):126-30. PubMed ID: 20109337
[TBL] [Abstract][Full Text] [Related]
16. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies.
Bache M; Kappler M; Said HM; Staab A; Vordermark D
Curr Med Chem; 2008; 15(4):322-38. PubMed ID: 18288988
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for tirapazamine in the treatment of cervical cancer?
Ghatage P; Sabagh H
Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1589-97. PubMed ID: 23033890
[TBL] [Abstract][Full Text] [Related]
18. Exploitation of the HIF axis for cancer therapy.
Escuin D; Simons JW; Giannakakou P
Cancer Biol Ther; 2004 Jul; 3(7):608-11. PubMed ID: 15197342
[TBL] [Abstract][Full Text] [Related]
19. Targeting hypoxia for sensitization of tumors to radio- and chemotherapy.
Ghattass K; Assah R; El-Sabban M; Gali-Muhtasib H
Curr Cancer Drug Targets; 2013 Jul; 13(6):670-85. PubMed ID: 23687923
[TBL] [Abstract][Full Text] [Related]
20. Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.
Lunt SJ; Telfer BA; Fitzmaurice RJ; Stratford IJ; Williams KJ
Clin Cancer Res; 2005 Jun; 11(11):4212-6. PubMed ID: 15930359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
